FDA Grants Breakthrough Status to New 10-Cancer Blood Screening Test

SINGAPORE – May 28, 2026 – A novel blood test capable of screening for ten different types of cancer has received Breakthrough Device Designation from the U.S. Food and Drug Administration, a move that signals a significant step forward in the race to detect cancer earlier. The test, SPOT-MAS 10, developed by the global biotechnology company Gene Solutions, uses a single blood draw to identify cancer-associated signals, potentially revolutionizing how doctors screen for some of the deadliest diseases.

The designation, announced on Monday, is intended to expedite the development and regulatory review of medical devices that could provide more effective diagnosis for life-threatening conditions. While it is not a final marketing approval, the status provides Gene Solutions with a prioritized channel of communication with the FDA as it advances its plans for a U.S. launch, targeted for late 2026.

"Receiving FDA Breakthrough Device Designation for SPOT-MAS 10 is a defining milestone for Gene Solutions and reflects the potential of our multi-omic approach in cancer screening," said Dr. Nguyen Hoai Nghia, CEO & Co-founder of Gene Solutions, in a statement. "This recognition strengthens our commitment to advancing accessible, evidence-based technologies that support earlier detection of cancers, especially for those where screening options remain limited."

A Multi-Omic Approach to Screening

At the heart of SPOT-MAS 10 is a sophisticated, multi-layered analytical method. The test examines cell-free DNA (cfDNA)—tiny fragments of genetic material shed by cells into the bloodstream—for two distinct types of biological clues: DNA methylation and fragmentomics. Methylation patterns can indicate abnormal gene activity associated with cancer, while fragmentomics analyzes the size and patterns of the DNA fragments themselves, which can differ between healthy and cancerous cells.

A proprietary machine-learning algorithm then integrates these complex datasets to detect a cancer-associated signal. This multi-omic strategy is designed to enhance the test's accuracy and specificity, which is critical for a screening tool intended for a broad, asymptomatic population.

"Early cancer detection requires more than identifying a single molecular signal," explained Dr. Le Son Tran, the Principal Investigator for SPOT-MAS. "By integrating multiple layers of cell-free DNA information with machine learning, SPOT-MAS is designed to extract deeper biological signals from blood while maintaining the high specificity required for responsible screening."

The test is intended for use as an adjunctive screening tool in adults aged 40 and older. It aims to assist in the detection of breast, lung, liver, colorectal, gastric, ovarian, pancreatic, esophageal, endometrial, and head & neck cancers—a list that includes several malignancies for which no effective population-wide screening currently exists.

Navigating a Competitive Field

Gene Solutions enters a dynamic and highly competitive U.S. market for multi-cancer early detection (MCED) tests, often called liquid biopsies. The field is dominated by several well-funded players, including Grail, a subsidiary of Illumina, whose Galleri test is already available as a laboratory-developed test. Other major competitors include Exact Sciences, the company behind Cologuard, and Guardant Health, which are both advancing their own MCED technologies.

However, Gene Solutions arrives with significant clinical and real-world data from Asia. In March 2025, the company completed the K-DETEK study, a large prospective validation trial involving over 9,000 asymptomatic participants. The results, published in the journal BMC Medicine, reportedly demonstrated strong performance. Furthermore, the test has already been used by more than 100,000 individuals in real-world clinical practice, providing a wealth of data on its performance outside of controlled study settings. This extensive evidence base from Asia could provide a crucial advantage as the company navigates the rigorous U.S. regulatory and commercial landscape.

The Path to Market: Hurdles Beyond Approval

The FDA's Breakthrough Device Designation is a powerful accelerator, but it marks the beginning, not the end, of the journey to widespread clinical adoption. To succeed in the U.S., Gene Solutions must clear several formidable hurdles. The first is securing full FDA marketing authorization, which will require demonstrating both analytical and clinical validity to the agency's exacting standards.

Perhaps the greatest challenge lies in reimbursement. For SPOT-MAS 10 to become a routine part of preventive care, Gene Solutions must convince public and private payers, including the Centers for Medicare & Medicaid Services (CMS), that the test is not only effective but also cost-effective. This requires demonstrating clinical utility—proof that using the test leads to better patient outcomes, such as catching cancers at an earlier, more treatable stage and ultimately saving lives, in a way that justifies its cost.

Building this case will involve extensive health economics and outcomes research. The company will also need to focus on educating physicians on how to properly integrate the test into their practices, manage patient expectations, and follow up on positive results, which require confirmatory diagnostic procedures. Gene Solutions has stated that SPOT-MAS 10 is designed to complement, not replace, existing guideline-recommended screenings like mammograms and colonoscopies, a key message for both clinicians and patients.

With its U.S. laboratory and validation strategy underway, Gene Solutions is focused on generating the necessary evidence to support the responsible implementation of its technology. The company's progress will be closely watched by the medical community, investors, and millions of people hopeful for more powerful tools in the global fight against cancer.